RANIHealthcare · BiotechnologyThe 5 Wall Street analysts covering Rani Therapeutics Holdings, Inc. hold a median 12-month price target of $6 — +891.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 28 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Rani Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (93): Sales and profits are climbing, and climbing faster than before.
Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RANI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +891.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | Chardan Capital | Maintains | Buy | $6.00 |
| 21 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $11 |
| 21 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Aug 2026 | Chardan Capital | Initiates | Buy | $6.00 |
| 18 Aug 2026 | Chardan Capital | Initiates | Buy | — |
| 20 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 20 May 2026 | Canaccord Genuity | Maintains | Buy | $5.00 |
| 1 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Oct 2025 | HC Wainwright & Co. | Assumes | Buy | $11 |
| 20 Oct 2025 | Maxim Group | Maintains | Buy | — |
| 16 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Aug 2024 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RANI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Rani Therapeutics Holdings, Inc. returned −63.5% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 9% of US stocks
Cheaper than 48% of US stocks
Cheaper than 69% of US stocks
Higher than 28% of US stocks
Higher than 97% of US stocks
Higher than 8% of US stocks
Higher than 30% of US stocks
Higher than 8% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rani Therapeutics Holdings, Inc. has a market value of $86.4M and an enterprise value of $29.9M.
Revenue in the twelve months to 30 June 2026: $4.9M. The latest quarter grew 0.0% year on year.
Net income over the same four quarters: −$33.4M, a −685.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.27.
Free cash flow in the twelve months to 30 June 2026: −$20.3M.
Trailing P/E: −1.4×; forward P/E: −3.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rani Therapeutics Holdings, Inc. employs 69 people — $71K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rani Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rani Therapeutics outlined progress in its oral biologics delivery platform, including plans to advance obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai.
Why it matters — The update highlights development plans and anticipated collaboration milestones that RANI watchers may track.
Rani Therapeutics announced that its management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference.
Why it matters — The announcement provides RANI watchers with information about an upcoming management appearance at an industry conference.
Rani Therapeutics announced that its RaniPill platform technology has been accepted into the U.S. FDA's Emerging Technology Program (ETP). Acceptance into the program enables early FDA engagement to support development of the RaniPill platform.
Why it matters — A RANI watcher would care because early FDA engagement through the ETP could help streamline and support the regulatory development of the company's RaniPill platform technology.
Rani Therapeutics announced that its management team will participate in upcoming conferences in September. The announcement was made on September 8, 2026, by the clinical-stage biotherapeutics company focused on oral delivery of biologics.
Why it matters — The participation gives Rani watchers an opportunity for management to present and discuss the company's progress in oral biologic delivery with investors and industry peers.
Top Wall Street analysts changed their outlooks on several names, with the article highlighting five analyst coverage initiations for Tuesday, including a Definium Therapeutics analyst beginning coverage on a bullish note. The item directs readers to a full analyst ratings page for all upgrades, downgrades, and initiations.
Why it matters — A RANI watcher would care because analyst coverage initiations and rating changes can draw investor attention and affect market sentiment toward stocks generally and within the biotech/therapeutics space.
The 5 Wall Street analysts covering Rani Therapeutics Holdings, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Rani Therapeutics Holdings, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rani Therapeutics Holdings, Inc. 73 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Rani Therapeutics Holdings, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +891.1% from the last close, and Ticker Nerd's factor model ranks Rani Therapeutics Holdings, Inc. 73 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rani Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $11 over the next 12 months.
Rani Therapeutics Holdings, Inc. returned -63.5% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs.
The most recent item we track (MarketBeat, 22 Oct 2026): "Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances". Rani Therapeutics outlined progress in its oral biologics delivery platform, including plans to advance obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai.
Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions. Rani Therapeutics develops this technology for use across multiple therapeutic areas, including peptides, proteins, antibodies, and oligonucleotides. Its business is centered on advancing drug-delivery solutions that may support patients, physicians, and healthcare systems by making biologic administration more convenient. The company operates in the biotechnology and health care life sciences sectors, where oral delivery platforms are an important area of innovation.
CEO Mr. Talat Imran · 69 employees · United States · https://www.ranitherapeutics.com
